# Efficacy of Topical Epinastine Eyelid Cream for Perennial Allergic Conjunctivitis: A Prospective Study

**Authors:** Hayato Tanaka, Mao Tanabe, Ayaka Kawaguchi, Hitoshi Tabuchi, Atsuki Fukushima

PMC · DOI: 10.7759/cureus.85364 · Cureus · 2025-06-04

## TL;DR

A study found that a once-daily eyelid cream containing epinastine significantly reduced eye itch and improved quality of life for patients with perennial allergic conjunctivitis.

## Contribution

This study introduces a new once-daily eyelid cream formulation of epinastine for managing allergic conjunctivitis symptoms.

## Key findings

- Ocular itch scores significantly decreased from baseline to the next morning (P = 0.003).
- Daytime quality of life scores improved significantly after the first and second applications (P < 0.001).
- All 14 patients completed the study, indicating good compliance with the eyelid cream regimen.

## Abstract

Introduction: Antihistamine eye drops are first-line treatments for allergic conjunctivitis; however, patient compliance and ocular itch exacerbation during medication intervals remain challenging. This study investigated the clinical application of 0.5% topical epinastine eyelid cream in patients with symptomatic perennial allergic conjunctivitis already using antihistamine eye drops.

Methodology: Fourteen patients with perennial allergic conjunctivitis using antihistamine eye drops were prescribed 0.5% topical epinastine eyelid cream. Patients applied the cream once daily before bedtime. Questionnaires assessed medication compliance, 24-hour ocular itch scores, and daytime quality of life (QOL). Statistical analysis used a mixed-effect model for repeated measures.

Results: All 14 patients completed the proactive eyelid cream medication. Ocular itch scores significantly decreased from baseline to the next morning (P = 0.003). Daytime QOL scores showed significant changes between baseline and first and second applications (P < 0.001 for both).

Conclusions: A 0.5% topical epinastine eyelid cream demonstrates potential as a convenient, once-daily treatment for allergic conjunctivitis, offering consistent symptom control and improved patients' QOL. Further long-term studies are recommended to validate these initial findings.

## Linked entities

- **Chemicals:** epinastine (PubChem CID 3241)
- **Diseases:** allergic conjunctivitis (MONDO:0005642)

## Full-text entities

- **Diseases:** Allergic Conjunctivitis (MESH:D003233), Ocular itch (MESH:D011537)
- **Chemicals:** Epinastine (MESH:C053090)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12227237/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12227237/full.md

## References

8 references — full list in the complete paper: https://tomesphere.com/paper/PMC12227237/full.md

---
Source: https://tomesphere.com/paper/PMC12227237